©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Identification of the Peptides That Stimulate the Phosphoinositide Hydrolysis in Lymphocyte Cell Lines from Peptide Libraries (*)

(Received for publication, November 1, 1995; and in revised form, January 16, 1996)

Suk Hwan Baek Jeong Kon Seo Chi-Bom Chae Pann-Ghill Suh Sung Ho Ryu (§)

From the Department of Life Science, Pohang University of Science and Technology, San 31 Hyojadong, Pohang Kyungbuk 790-784, Korea

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Peptides which stimulate the formation of inositol phosphates (InoPs) in lymphocyte cell lines were identified by screening synthetic peptide libraries composed of random sequences of hexapeptides. The peptides containing the consensus sequence XKYX(P/V)M were found to be most active in the phospholipase C (PLC)-mediated formation of InoPs in a human B myeloma cell line, U266. The peptides also stimulated the phosphoinositide hydrolysis and the release of [Ca] in HL60 and U937 cell lines. On the other hand, these peptides showed no effect in the following cell lines: NIH3T3, PC12, Daudi, Sp2, Jurkat, H9, Molt-4, SupT-1, K562, and RBL-2H3. The result suggests the possibility that the peptides may have cell type specificity. Experiments with one of the active peptides, WKYMVM-NH(2) showed that its action mimics the effect of AlF(4) which is a G-protein activator in the InoPs generation, and pertussis toxin partially blocked the InoPs accumulation and [Ca] release induced by the peptide in the U266 cells. Binding assays with the peptide labeled with I showed that U266 cells have a saturable number of binding sites for the peptide. Taken together, these results suggest that the peptides could activate PLC-mediated signal transduction via a pertussis toxin-sensitive G-protein coupled receptor in certain cell types.


INTRODUCTION

Many biological actions such as ligand-receptor interactions are based on the specificity of proteins conferred by the primary sequence of amino acids as well as the secondary and tertiary structures dictated by the primary sequence. Of special importance is the formation of local environments, such as active site and motif, which play a key role in the function of a protein. Among the random sequences of short peptides, there may be sequence(s) which can act on such local environments, and these sequences could serve as the lead for the development of effective new drugs. Recently various methods have been developed for identification of the sequence(s) of interest from vast mixtures of random peptide sequences or polymers (template) with various side chain groups (chemical diversity libraries) within a short period of time with minimal effort(1, 2, 3, 4, 5) . Successful screening of these libraries has been described not only for epitopes recognized by monoclonal antibodies(6, 7, 8) , but also for the identification of the biologically active peptides such as antibacterial and antifungal peptides(2) , human immunodeficiency virus protease inhibitors(9) , substrate-analog trypsin inhibitors(10) , and interleukin-8-specific antagonist(11) .

Phosphoinositide-specific phospholipase C (PLC) (^1)plays a pivotal role in the signal pathway for cell growth and differentiation(12, 13) . The activated PLC catalyzes hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP(2)) into two intracellular second messengers, inositol 1,4,5-trisphosphate (IP(3)) and diacylglycerol (DAG). The IP(3) induces an increase in intracellular free calcium concentration ([Ca]), while DAG directly activates protein kinase C(14, 15, 16, 17) . On the basis of amino acid sequence similarity, the PLCs in mammalian tissue have been divided into three types (PLC-beta, -, and -), each of which comprises more than one subtype(18, 19, 20, 21, 22) .

Generally, in mature B lymphocytes, interaction of ligands with the membrane-bound immunoglobulin triggers a series of metabolic events including the rapid activation of a protein tyrosine kinase associated with the B-cell receptor(23, 24, 25) . The activation of these kinases leads to the rapid tyrosine phosphorylation of a number of substrates including the phospholipase C (PLC)-1 and PLC-2(26, 27, 28, 29) . It is assumed that the phosphorylation of PLC- type will lead to enzymatic activation. Therefore, the activation of protein tyrosine kinase and PLC- appears to be essential for ligand-mediated B-cell activation.

A GTP-binding protein (G-protein) that has been postulated as a modulator of the PLC-beta activity has partially been characterized at the molecular level(30, 31, 32) . B cells that have been treated with tyrosine kinase inhibitors (genistein, herbimycin, tyrphostin) can still undergo phosphoinositide (PI) hydrolysis. The cells also display increases in [Ca] when stimulated directly through G-proteins by AlF(4)(28, 33) . Similarly, inactivation of the B-cell receptor abolishes subsequent tyrosine kinase activation, although the cells continue to respond to the G-protein-activating agent, mastoparan(34) . These observations suggest that B-cell activation may involve PLC-beta types or another isoform of PLC that can be mediated by G-proteins independently of tyrosine phosphorylation of PLC- types. PLC-beta types are shown to be activated by members of the G or G subunit of hetertrimeric G-protein(30, 35) . However, the implication of G-protein in B-cell activation remains to be characterized.

In this study, we have identified peptides which stimulate the formation of InoPs in cells from libraries of hexapeptides. The peptides appear to have positive effects on the formation of InoPs and [Ca] release in certain cell types such as U266 (human B myeloma), HL 60 (human promyelocytic lymphoma), and U937 (human histiocytic lymphoma). These effects appear to be mediated through the binding of the peptide to cell-surface receptors.


EXPERIMENTAL PROCEDURES

Materials

Fmoc amino acids were obtained from Millipore Co (Bedford, MA). Rapidamide resin was purchased from DuPont (Boston, MA). Myo-[2-^3H]inositol and the ECL kit were purchased from Amersham Corp. (Bucks, UK). Fura-2 pentaacetoxymethyl ester (Fura-2/AM) and 1, 2-bis(2-aminophenoxy)ethane-N,N,N`N`-tetraacetoxymethyl ester (BAPTA/AM) were purchased from Molecular Probes (Eugene, OR). RPMI 1640 was obtained from Life Technologies, Inc. Dialyzed fetal bovine serum and supplemented bovine calf serum were purchased from Hyclone Laboratories Inc. (Logen, UT).

Cell Culture

The U266 B myeloma cell and other cell lines were purchased from the ATCC, Rockville, MD, and maintained in RPMI 1640 medium supplemented with 10% fetal calf serum. Cells were maintained at densities of 2 times 10^5 cells/ml at 37 °C in a humidified incubator supplied with 95% air and 5% CO(2).

Preparation of Positional Scanning-Synthetic Peptide Combinatorial Libraries (PS-SPCLs)

Libraries were synthesized according to the protocol of Houghten et al.(2) and Pinilla et al.(5) . Briefly, PS-SPCLs, consisting of six-residue peptide sequences having free N termini and amidated C termini, were synthesized. A single position in each peptide mixture was individually and specifically defined with 19 of the 20 natural L-amino acids (cysteine excluded), while the five remaining positions consisted of mixtures of the same 19 amino acids. Defined positions are represented by O and the positions with mixed amino acids are represented by X. The six sets of PS-SPCLs (total 114 pools) are represented by the formula; O(1)XXXXX-NH(2), XO(2)XXXX-NH(2), XXO(3)XXX-NH(2), XXXO(4)XX-NH(2), XXXXO(5)X-NH(2), and XXXXXO(6)-NH(2). Libraries of peptides were constructed on Rapidamide resin beads as described elsewhere(36) . Fmoc chemistry was used. The resin beads were distributed into different reaction vessels for each amino acid at each coupling step; pooled, washed, and thoroughly mixed for randomization; deprotected; and redistributed into the various vessels again for the next coupling step and so forth. The amount of each amino acids used to yield approximately equimolar coupling was determined empirically. The completeness of each reaction was checked with ninhydrin(37) . Side chains were deprotected with a mixture of trifluoroacetic acid (ethanedithiol:water:thioanisole; 90:5:4:1, vol/vol). The 114 peptide mixtures were individually extracted with water, lyophilized, and dissolved in water at a final concentration of 27 nM for a peptide sequence in each pool.

Synthesis of Individual Peptides

The peptides with known sequences were synthesized on a Rapidamide resin as carrier. Briefly, peptides were assembled via standard Fmoc/t-butyl strategy on an acid-labile linker. Upon treatment with trifluoroacetic acid, the peptides were cleaved and released as amides at their C-terminal position.

Peptide Analysis

The efficiency of coupling was determined by analyzing the peptide solution, before and after coupling, by reversed-phase HPLC and by reading the absorbance at 215 nm. The peptides were characterized by chromatography on a C18 reversed-phase HPLC column (Vydac, 218TP1022, 22 times 300 mm). The peptides were eluted with 0-40% gradient of CH(3)CN in 0.05% trifluoroacetic acid. The composition of the peptides was confirmed by amino acid analysis(38) , and the peptides were sequenced by using an Applied Biosystems 473A protein/peptide microsequencer.

Measurement of Inositol Phosphates Induced by Peptides

The cells grown in culture were harvested by centrifugation, washed with inositol-free RPMI 1640 medium, and resuspended at a density of 2 times 10^6 cell/ml in the same medium. The cells were labeled with myo-[^3H]inositol (1 µCi/10^6 cell, Amersham) for 24 h at 37 °C and rinsed twice with inositol-free RPMI 1640 medium containing 0.5% fetal bovine serum, 20 mM Hepes, pH 7.2, 20 mM LiCl, and bovine serum albumin (1 mg/ml) and resuspended at a density of 2 times 10^7 cells/ml. A portion (0.1 ml) of the cell suspension was transferred to a microcentrifuge tube and incubated at 37 °C for 15 min. Stimulation of PIP(2) hydrolysis was initiated by addition of peptides or solvents for indicated time, and the reaction terminated by the addition of 0.1 ml of ice-cold 5% perchloric acid (HClO(4)). After 30 min in an ice bath, the tubes were centrifuged, and the supernatants were diluted 5-folds with distilled water and applied to Bio-Rad Dowex AG 1-X8 anion exchange columns. Each column was then washed with 2 ml of distilled water followed by 10 ml of 60 mM ammonium formate containing 5 mM sodium tetraborate. Total inositol phosphates were eluted with a solution containing 1 M ammonium formate and 0.1 M formic acid. To determine IP(3), the columns was first washed with 0.4 M ammonium formate and 0.1 M formic acid, and then IP(3) was eluted with 0.8 M ammonium formate and 0.1 M formic acid. Radioactivity of [^3H]inositol phosphates was determined by counting in a scintillation counter (Tri-Packard, Meriden, CT).

Measurement of [Ca](i)

The level of intracellular Ca was determined using fura-2/AM(39) . Briefly, cells were incubated in serum-free RPMI 1640 medium with 3 µM fura-2/AM at 37 °C for 50 min with continuous stirring. The cells were washed with serum-free RPMI 1640 medium. Sulfinpyrazone (250 µM) was included in all solutions to prevent dye leakage from the cells. Before the measurement, a small portion of the cells was aliquoted into a centrifuge tube and centrifuged. The pelleted cells were resuspended in Ca-free Locke's solution (158.4 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl(2), 5 mM Hepes, 10 mM glucose, and 0.2 mM EGTA, pH 7.3). Changes in fluorescence ratio were determined at dual excitation wavelengths of 340 and 380 nm and emission wavelength of 500 nm. The calibration of the fluorescence ratio in terms of [Ca](i) was performed according to Grynkiewicz et al.(40) .

Cell Binding Experiments

Peptide (MKYMPM-NH(2)) was radiolabeled with I (IODO-GEN, Pierce)(41) . U266 cells were suspended in phosphate-buffered saline, pH 7.4 containing 0.1% bovine serum albumin. Binding was initiated with the addition of various amounts of I-labeled peptide. Equilibrium binding was established at room temperature for 90 min and terminated by rapid filtration through multiscreen-FB filters (Millipore Co.) followed by five washes with ice-cold binding buffer. The radioactivity of the punched filter membrane was determined in a -counter. The level of specific binding was determined after correction for the nonspecific binding occurring in the presence of 250-fold excess unlabeled peptide.


RESULTS

The testing of each of total 114 peptide pools of PS-SPCLs permits the determination of the most effective amino acid at each of the six positions in a hexapeptide. The results of the initial screening of the peptide library are shown in Fig. 1. The peptide mixtures, WXXXXX-NH(2), was found to strongly stimulate the formation of InoPs in U266 cells. The amino acids with slightly less active than tryptophan (W) at the first position were methionine (M) and arginine (R). For the second position, several amino acids appear to be active, lysine (K) and histidine (H) being slightly more active than others. The active amino acids at the third position were tyrosine (Y) and phenylalanine (F), tyrosine being slightly more active. The most active amino acid at the fourth position were methionine (M). Valine (V) and proline (P) appear to be more active than other amino acids at the fifth position. The sixth position showed marked contrast between the active amino acid (methionine, M) and other amino acids.


Figure 1: Initial screening of the PS-SPCLs for the peptides which stimulate the formation of InoPs. Each panel represents the result obtained with the peptide pools with the known amino acids at each of the six positions of hexapeptides. The six positions are individually defined (O(1) and O(2) . . .) with each of the 19 L-amino acids. The remaining five positions consist of mixtures (X) of 19 L-amino acids (cysteine excluded). The library consists of 114 peptide pools; the PS-SPCL in total is made up of 47,045,881 different peptides. U266 cells (2 times 10^6) were prelabeled with [^3H]inositol (1 µCi/10^6 cell) for 24 h in inositol-free medium. The cells were then rinsed and incubated for 15 min in LiCl mixture and stimulated with peptide mixture. [^3H]InoPs formations were analyzed as described under ``Experimental Procedures.'' Each bar represents the inositol phosphates formation stimulated by a peptide pool.



The amino acids chosen for reiterative synthesis of peptides were as follows: 1st, W, M, and R; 2nd, K and H; 3rd, Y and F; 4th, M, V, and I; 5th, P, V, and R; and sixth, M. The selected amino acids at 4th, 5th, and 6th position were linked in all combinations, and for the 1st, 2nd, and 3rd positions the mixtures of the selected amino acids used were: X(1)X(2)X(3)MPM-NH(2), X(1)X(2)X(3)MVM-NH(2), X(1)X(2)X(3)MRM-NH(2), X(1)X(2)X(3)VPM-NH(2), X(1)X(2)X(3)VVM-NH(2), X(1)X(2)X(3)VRM-NH(2), X(1)X(2)X(3)IPM-NH(2), X(1)X(2)X(3)IVM-NH(2), X(1)X(2)X(3)IRM-NH(2). X(1): W, M, R; X(2): K, H; X(3): Y, F.

The reiterative synthesis generates nine peptide pools containing 3 times 2 times 2 times 3 times 3 times 1 = 108 individual hexapeptides. The nine peptide pools were tested for stimulation of the formation of InoPs. Among these, XXXMPM-NH(2), XXXMVM-NH(2) and XXXVPM-NH(2) were found to be more active than others for formation of InoPs (Fig. 2A). Each active peptide pools was resolved and purified by using HPLC on a C18 column. Each peak fraction from the C18 column was tested for effect on the formation of InoPs, and the amino acid sequence of the active fractions were determined. Fig. 2B shows the result obtained with one of the active peptide WKYMVM-NH(2). The peptide showed the half maximal activity at about 6 times 10M. Also, most of the active peptides have a consensus of XKYX(P/V)M. A time course study showed that the formation of IP(3) reached a maximal level in 5 min and returned to a basal level in 20 min after the addition of the peptide to U266 cells. However, the formation of total InoPs was consistently elevated throughout the 20 min incubation with the peptides (data not shown).


Figure 2: Effect of the peptide pools synthesized from the selected amino acids and the single selected peptide for their ability to stimulate the InoPs formation in U266 cell line. A, the first three positions consist of mixture (X) of defined amino acid (X(1): W, M, R; X(2): K, H; X(3): Y, F). The remaining three positions were individually defined with each of the selected amino acids. The partial library consists of 9 mixtures; each mixture contains 12 single peptides. The total number of peptides in 9 mixtures were 12 times 9 = 108. Error bars were omitted for clarity of the figure. B, A peptide WKYMVM-NH(2) selected from the experiment described above was tested for stimulation of InoPs formation in U266 cells.



IP(3) is one of the major second messengers that triggers Ca release from the internal Ca pools in the cell. Generally, the elevation of [Ca](i) is achieved by both Ca release from the internal stores as well as by influx from the extracellular environment. Fig. 3A shows that there was peptide dose-dependent increase of [Ca]. In order to determine the peptide-induced Ca release from the internal stores, we measured the Ca mobilization of U266 cell in Ca-free medium containing 0.2 mM EGTA. In addition, depleting intracellular free Ca by preloading U266 cells with the Ca-buffering agent BAPTA completely inhibited the change in [Ca] at maximal effective concentration of the peptide (Fig. 3B). These results demonstrate that the [Ca] increase induced by the peptide was not due to mobilization from the extracellular Ca, but from the intracellular Ca reservoir.


Figure 3: Changes in [Ca] after treatment with peptide in the absence of external Ca. A, [Ca] was determined fluorometrically using fura-2/AM as described under``Experimental Procedures.'' Before measurement, U266 cells (2 times 10^6) were suspended in Ca-free Locke's solution containing 0.2 mM EGTA. Cells were treated with various concentrations of WKYMVM-NH(2) where indicated by the arrow. B, U266 cells in upper trace were stimulated with excess WKYMVM-NH(2). Cells used in the lower trace (+ BAPTA label) had been preincubated in RPMI containing 60 µM BAPTA acetoxymethyl ester for 30 min at 37 °C.



In order to investigate if the peptides have a general effect on other cell types, we examined the effect of an active peptide (WKYMVM-NH(2)) on the formation of InoPs in NIH3T3 (NIH Swiss mouse embryo fibroblast) and PC12 (rat adrenal pheochromocytoma) cells. It showed no effect on either cells (Fig. 4). Daudi (human Burkitt lymphoma), Sp2 (mouse myeloma), Jurkat (human acute T-cell leukemia), H9 (human T-cell lymphoma), Molt-4 (human peripheral blood T cell), SupT-1 (human T-cell lymphoblastic lymphoma), K562 (human chronic myelogenous leukemia), RBL-2H3 (rat mast cell), U937 and HL60 cells were tested for the effect of the peptide in a variety cell types originated from hemopoietic lineage. Among these cells, the peptide stimulated the formation of InoPs only in HL60 and U937 cell lines (Fig. 4). The results suggest that the peptides increase the formation of InoPs only in cell type-specific manner.


Figure 4: Stimulation of InoPs formation by a peptide in various cell lines. Subconfluent cultures of each type were prelabeled with myo-[^3H]inositol (1 µCi/10^6 cell) for 24 h in serum-free RPMI media. Cells were then treated with peptides (WKYMVM-NH(2), 1 µM) in RPMI containing 20 mM Hepes, pH 7.2, 20 mM LiCl, and 1 mg/ml bovine serum albumin for 10 min at 37 °C, and [^3H]InoPs were extracted and separated by Dowex AG 1-X8 column as described under ``Experimental Procedures.'' Results are presented as the total InoPs and expressed as mean ± S.D. from three independent experiments done in duplicate.



PLC- is activated by phosphorylation of specific tyrosine residues. The activated PLC- catalyzes hydrolysis of PIP(2) into two intracellular second messengers, IP(3) and DAG(19) . It is assumed that the phosphorylation of PLC- will lead to its activation. Experiments were therefore performed to investigate whether tyrosines of PLC- were phosphorylated in U266 cells in response to the peptides and whether the time course of the phosphorylation was compatible with the changes in the InoPs formation. However, there were no appreciable changes in the level of tyrosine phosphorylation of PLC 1 and 2 enzymes within the time period examined, although PLC 1 and 2 were clearly detectable in U266 cells (data not shown). This result suggests that the peptides may not induce PI hydrolysis and [Ca](i) release through the activation of PLC- type.

To investigate the possible involvement of a G-protein in the peptide-induced formation of InoPs, U266 cells were treated with pertussis toxin (150 ng/ml) for 12 h prior to the addition of WKYMVM-NH(2). The peptide-dependent formation of InoPs was reduced by 70% (Fig. 5). AlF(4) as a G-protein activator induced the InoPs formation in U266 cells. In addition, increasing amounts of WKYMVM-NH(2) in the presence of a fixed amount of AlF(4) showed no additive effect on the formation of InoPs (Fig. 6). These results support that pertussis toxin-sensitive G-proteins may be involved in the PLC-beta mediated PI hydrolysis in response to the peptides in U266 cells.


Figure 5: Effects of pertussis toxin on the peptide-induced formation of InoPs in U266 cells. Subconfluent cultures of each cell lines were prelabeled with myo-[^3H]inositol (1 µCi/10^6 cell) for 24 h in serum-free RPMI media. U266 cells were treated with indicated concentration of WKYMVM-NH(2) in the absence (bullet) or presence (circle) of 150 ng/ml of pertussis toxin for 12 h, and [^3H]InoP formations were analyzed as described under ``Experimental Procedures.'' Results are expressed as means ± S.D. from three independent experiments.




Figure 6: Lack of additive effect on the formation of InoPs by AlF(4) and WKYMVM-NH(2). myo-[^3H]Inositol-labeled cells were incubated with the indicated concentrations of WKYMVM-NH(2) in the presence of AlF(4) (20 µM AlCl3/10 mM NaF) after then, perchloric acid added and InoPs formation was quantitated as described under ``Experimental Procedures.'' The data are the mean ± S.D. of triplicate determinants.



To investigate the possible action of the peptide through the binding to a cell-surface receptor, a fixed number of U266 cells was incubated for 90 min at room temperature in the presence of the various concentrations of I-labeled peptide. After washing the cells, we determined the amount of bound I-labeled peptide using multiscreen binding assay system (Millipore). A representative result of these assays is shown in Fig. 7. As the concentration of I-labeled peptide increased, there was a corresponding increase in the amount of the peptide bound to the cells until it reached a plateau, suggesting that there is a saturable number of binding sites for the peptide on the surface of U266 cells. On the other hand, fMLP is known as the peptide that stimulates the formation of InoPs through the cell-surface receptor which is coupled with a G-protein in neutrophils(42, 43, 44) . Thus, it was possible that the peptides we have identified in this study act on the fMLP receptor. However, fMLP showed no effect on the formation of InoPs in U266 cells (Fig. 8). Therefore, it appears that our peptide does not bind to the fMLP receptor.


Figure 7: Binding of I-MKYMPM-NH(2) to U266 cells. U266 cells (10^6) in 0.2 ml of phosphate-buffered saline containing 0.1% bovine serum albumin were incubated with an increasing concentrations of I-MKYMPM-NH(2) for 90 min at room temperature. Each data point represents specific binding, which was computed by subtracting nonspecific binding in the presence of excess unlabeled peptide from total binding. Data are presented as means ± S.E. of the separate experiments, each performed in triplicate. Error bars were omitted for clarity of the figure.




Figure 8: Lack of effect by fMLP on the formation of InoPs in U266 cells. myo-[^3H]Inositol-labeled cells were incubated with the indicated concentrations of WKYMVM-NH(2) or fMLP, then perchloric acid was added, and InoP formation was quantitated as described under ``Experimental Procedures.'' The data are the mean ± S.D. of triplicate determinants.




DISCUSSION

In this study, we have found that the hexapeptides with the following consensus sequence XKYX(P/V)M (where X is any amino acid) stimulate the formation of InoPs in the B lymphocyte cell types through the action of PLC via a pertussis toxin-sensitive G-protein coupled cell-surface receptor. These peptides were identified by screening the Positional Scanning Synthetic Peptide Combinatorial Libraries described by Houghten et al.(2) in which each position of hexapeptide is fixed with a known amino acid and the rest of five positions are any of 20 amino acids (in this study cysteine was omitted).

Detailed studies with one of the active peptides WKYMVM-NH(2) suggest that the peptide stimulates the formation of InoPs only in certain cell types such as U266, HL60, and U937 cells. Up to now we do not know exactly what induced the differential effect on each cell types because of the limited information in cell expression patterns for putative receptors, G-proteins, and PLC isozymes. The pertussis toxin-sensitive G-proteins are inactivated by ADP-ribosylation on the alpha subunit and include members of G(i) or G(o) family(45) . In NIH3T3 and Sp2 cells, an increase in IP(3) and a subsequent transition increase in [Ca](i) were elicited through a pertussis toxin-sensitive manner by lysophosphatidic acid(46) . Also, C3a and lysophosphatidylserine stimulated the generation of IP(3) that was inhibited by pertussis toxin-sensitive G-protein signal pathway in mast cell(47, 48) . Nevertheless, our peptide have no effect on the formation InoPs in these NIH3T3, Sp2, and mast cells. Thus, the cell type-specific action of our peptide might be due to the existence of putative receptor specific for the peptide, rather than the difference of the downstream components which need for the pertussis toxin-sensitive InoPs formation. One of the major goals of future work is to identify the putative receptor for the peptide.

It is widely accepted that the hydrolysis of PIP(2) by PLC and subsequent formation of DAG and IP(3) is a major signaling pathway employed by a variety of hormones, growth factors, and various neurotransmitters(14, 15, 16, 17) . IP(3) stimulates the release of free Ca ions from intracellular Ca stores. Ca leads to the activation of one or more isozymes of protein kinase C, which may participate in the induction of various immediately early genes such as c-fos and c-myc(49) . Accordingly, peptide-induced IP(3) formation and the subsequent release of Ca is very important for B-cell activation. As in T lymphocytes, antigen receptor interaction in B cells leads to tyrosine phosphorylation of PLC-1 (28) , but also of PLC-2 that appears to be the major isozyme in B cells(50) . Recently, tyrosine phosphorylation of PLC-2 was reported to be induced in murine B cells upon cross-linking of membrane immunoglobulins (29, 30) and in the HL60 granulocytes stimulated with pervanadate(51) . In most cases, the tyrosine phosphorylation of PLC- is accompanied by changes in PI turnover. Despite this correlation, however, the peptides do not affect phosphorylation of the tyrosines of PLC-1 and -2 enzymes. These results suggest that another isoform of PLC may be involved in the formation of InoPs in the B cells treated with the peptides.

In this report, we suggest that the pertussis toxin-sensitive G-protein is directly involved in the peptide-induced PI hydrolysis in B cells. This is evident from the observations that pertussis toxin inhibits the formation of InoPs and the release of [Ca](i) by WKYMVM-NH(2) (data not shown). Furthermore, the peptide-induced PI hydrolysis mimics the stimulatory effect by AlF(4) (G-protein activator). These data provide strong support for the contention that the peptide-mediated activation of PLC in U266 cell requires a G-protein, although an isoform of G-proteins are not presently identified. It is clear that the pertussis toxin-insensitive mechanism is mediated by alpha-subunits of the recently discovered G(q) family of G-proteins(52, 53) . However, the pertussis toxin-sensitive mechanism for activation of PLC is less well understood. Several recent reports suggest that the pertussis toxin-sensitive response can be reconstituted through receptor-mediated release of beta subunits from members of the G(i) class, and the toxin apparently blocks the activation of PLC-beta2 by interfering with the release of the beta subunits from the trimeric G-proteins(45, 54, 55) . In addition, we detected that the PLC-beta2 was preferentially expressed more than other beta-isoforms in U266 cell (data not shown). Therefore, PLC-beta2 may be potential mediator for the action of the peptides.

Experiments with the peptide labeled with I suggest that the cells have a saturable number of binding sites for the peptide on the cell surface, possibly a receptor. Presently we have no information on the nature of the receptor. It is likely that the formation of InoPs in response to the peptide is mediated through the interaction of the peptide to a cell-surface receptor. In addition, the peptide receptors may be different from the fMLP receptors because fMLP does not increase the level of InoPs in U266 cells. However, although peptide receptors are distinct from the fMLP receptors, it is possible that the two receptors share the same signal transduction pathways, because both fMLP and the peptide we reported here all stimulate PI hydrolysis in a pertussis toxin-sensitive manner.

For further study, the molecular characterization of the receptor, G-protein, and PLC related to this peptide signaling could provide the insight into the understanding of the ligand-triggered signal cascade in certain cell types.


FOOTNOTES

*
This work was supported in part by Pohang University of Science and Technology, Korea Green Cross Co., and Highly Advanced National Project from Ministry of Science and Technology, Korea. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 82-562-279-2292; Fax: 82-562-279-2199; sungho{at}vision.postec.ac.kr.

(^1)
The abbreviations used are: PLC, phospholipase C; PIP(2), phosphatidylinositol 4,5-bisphosphate; IP(3), inositol 1,4,5-trisphosphate; DAG, diacylglycerol; G-protein, GTP binding protein; InoP, inositol phosphate; PI, phosphoinositide; PS-SPCLs, positional scanning-synthetic peptide combinatorial libraries; fMLP, N-formyl-methionyl-leucyl-phenylalanine; Fmoc, N-(9-fluorenyl)methyl)oxycarbonyl; Fura-2/AM, fura-2 pentaacetoxymethyl ester; BAPTA/AM, 1,2-bis(2-aminophenoxy)ethaneN,N,N`N`-tetraacetoxymethyl ester.


REFERENCES

  1. Ostresh, J. M., Husar, G. M., Blondelle, S. E., Dorner, B., Weber, P. A., and Houghten, R. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11138-11142 [Abstract/Free Full Text]
  2. Houghten, R. A., Pinilla, C., Blondelle, S. E., Appel. J. R., Dooley, C. T., and Cuervo, J. H. (1991) Nature 354, 84-86 [CrossRef][Medline] [Order article via Infotrieve]
  3. Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. (1991) Nature 354, 82-84 [CrossRef][Medline] [Order article via Infotrieve]
  4. Zuckerman, R. N., Kerr, J. M., Siani, M. A., Banville, S. C., and Santi, D. V. (1992) Proc. Natl. Acad. Sci U. S. A. 89, 4505-4509 [Abstract]
  5. Pinilla, C., Appel, J. R., Blanc, P., and Houghten, R. A. (1992) BioTechniques 162, 901-905
  6. Felici, F., Castagnoli, L., Musacchio, A., Jappelli, R., and Cesareni, G. (1991) J. Mol. Biol. 222, 301-310 [Medline] [Order article via Infotrieve]
  7. Stephen, C. W., and Lane, D. P. (1992) J. Mol. Biol. 225, 577-583 [Medline] [Order article via Infotrieve]
  8. Luzzago, A., Felici, F., Tramontano, A., Pessi, A., and Cortese, R. (1993) Gene (Amst.) 128, 51-57
  9. Owens, R. A., Gesellchen, P. D., Houchins, B. J., and DiMarchi, R. D. (1991) Biochem. Biophy. Res. Commun. 181, 402-408 [Medline] [Order article via Infotrieve]
  10. Eichler, J., and Houghten, R. A. (1993) Biochemistry 32, 11035-11041 [Medline] [Order article via Infotrieve]
  11. Hayashi, S., Kurdowska, A., Miller, E. J., Albright, M. E., Girten, B. E., and Cohen, A. B. (1995) J. Immunol. 154, 814-824 [Abstract/Free Full Text]
  12. Rana, R., S., and Hokin, L. E. (1990) Physiol. Rev. 70, 115-164 [Free Full Text]
  13. Majerus, P. W. (1992) Annu. Rev. Biochem. 61, 225-250 [CrossRef][Medline] [Order article via Infotrieve]
  14. Nishizuka, Y. (1984) Nature 312, 315-321 [Medline] [Order article via Infotrieve]
  15. Berridge, M. J., and Irvine, R. F. (1984) Nature 312, 315-321 [Medline] [Order article via Infotrieve]
  16. Majerus, P. W., Ross, T. S., Cummingham, T. W., Caldwell, K. K., Jefferson, A. B., and Bansal, V. S. (1990) Cell 63, 459-465 [Medline] [Order article via Infotrieve]
  17. Nishizuka, Y. (1992) Science 258, 607-614 [Medline] [Order article via Infotrieve]
  18. Rhee, S. G., Suh, P. G., Ryu, S. H., and Lee, S. Y. (1989) Science 244, 546-550 [Medline] [Order article via Infotrieve]
  19. Park, D., Jhon, D. Y., Kriz, R., Knopf, J. L., and Rhee, S. G. (1992) J. Biol. Chem. 267, 16048-16055 [Abstract/Free Full Text]
  20. Jhon, D. Y., Lee, H. H., Park, D., Lee, C. W., Lee, K. H., Yoo, O. J., and Rhee, S. G. (1993) J. Biol. Chem. 268, 6654-6661 [Abstract/Free Full Text]
  21. Kim, M. J., Bahk, Y. Y., Min, D. S., Lee, S. J., Ryu, S. H., and Suh, P. G. (1993) Biochem. Biophys. Res. Commun. 194, 706-712 [CrossRef][Medline] [Order article via Infotrieve]
  22. Ferreira, P. A., Shortridge, R. D., and Pak, W. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6042-6046 [Abstract]
  23. Clark, M. R., Campbell, K. S., Kazlauskas, A., Johnson, S. A., Hertz, M., Potter, T. A., Pleiman, C., and Cambier, J. C. (1992) Science 258, 123-126 [Medline] [Order article via Infotrieve]
  24. Cambier, J. C. (1992) Curr. Opin. Immunol. 4, 257-264 [Medline] [Order article via Infotrieve]
  25. Weiss, A., and Littman, D. R. (1994) Cell 76, 263-274 [Medline] [Order article via Infotrieve]
  26. Rhee, S. G. (1991) Trends Biochem. Sci. 16, 297-301 [CrossRef][Medline] [Order article via Infotrieve]
  27. Sultzman, L., Ellis, C., Lin, L. L., Pawson, T., and Knopf, J. (1991 Mol. Cell. Biol. 11, 2018-2024
  28. Carter, R. H., Park, D. J., Rhee, S. G., and DeFranco, D. T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2745-2749 [Abstract]
  29. Hempel, W. M., Schatzman, R. C., and DeFranco, A. L. (1992) J. Immunol. 148, 3021-3027 [Abstract/Free Full Text]
  30. Park, D., Jhon, D. Y., Lee, C. W., Ryu, S. H., and Rhee, S. G. (1993) J. Biol. Chem. 268, 3710-3714 [Abstract/Free Full Text]
  31. Min, D. S., Kim, Y., Lee, Y. H., Suh, P. G., and Ryu, S. H. (1993) FEBS Lett. 331, 38-42 [CrossRef][Medline] [Order article via Infotrieve]
  32. Jiang, H., Wu, D., and Simon, M. I. (1994) J. Biol. Chem. 269, 7593-7596 [Abstract/Free Full Text]
  33. Lane, P. J. L., Ledbetter, J. A., McConnell, F. M., Draves, K. J., Deans, J., Schieven, G. L., and Clark, E. A. (1991) J. Immunol. 146, 715-722 [Abstract/Free Full Text]
  34. Cambier, J. C., Fisher, C. L., Pickles, H., and Morrison, D. C. (1990) J. Immunol. 145, 13-19 [Abstract/Free Full Text]
  35. Blank, J. L., Brattain, K. A., and Exton, J. H. (1992) J. Biol. Chem. 267, 23069-23075 [Abstract/Free Full Text]
  36. Houghten, R. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 5131-5135 [Abstract]
  37. Kaiser, E. T., Colescott, R. L., Blossinger, C. D., and Cook, P. I. (1970) Anal. Biochem. 34, 595-598 [Medline] [Order article via Infotrieve]
  38. Bidlingmeyer, B., Cohen, S., and Tarvin, T. (1984) J. Chromatogr. 336, 93-104 [Medline] [Order article via Infotrieve]
  39. Suh, B. C., Lee, C. O., and Kim, K. T. (1995) J. Neurochem. 64, 1071-1079 [Medline] [Order article via Infotrieve]
  40. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450
  41. Hulme, E. C. (ed) (1992) Receptor-Ligand Interactions: A Practical Approach , pp. 1-18, Oxford University Press, Oxford _
  42. Boulay, F., Tardif, M., Brouchon, L., and Vignais, P. (1990) Biochemistry 29, 11123-11133 [Medline] [Order article via Infotrieve]
  43. Sengelov, H., Boulay, F., Kjeldsen, L., and Borregaard, N. (1994) Biochem. J. 299, 473-479 [Medline] [Order article via Infotrieve]
  44. Prossnitz, E. R., Quehenberger, O., Cochrane, C. G., and Ye, R. D. (1993) J. Immunol. 151, 5704-5715 [Abstract/Free Full Text]
  45. Bristol, J. A., and Rhee, S. G. (1994) Trends Endocrinol. Metab. 5, 402-406
  46. Tigyi, G., Dyer, D. L., and Miledi, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1908-1912 [Abstract]
  47. Mousli, M., Hugli, T. E., Landry, Y., and Bronner, C. (1992) J. Immunol. 148, 2456-2461 [Abstract/Free Full Text]
  48. Lloret, S., and Moreno, J. J. (1995) J. Cell. Physiol. 165, 89-95 [Medline] [Order article via Infotrieve]
  49. Klemsz, M. J., Justement, L. B., Palmer, E., and Cambier, J. C. (1989) J. Immunol. 143, 1032-1039 [Abstract/Free Full Text]
  50. Coggeshall, K. M., McHugh, J. C., and Altman, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5660-5664 [Abstract]
  51. Bianchini, L., Todderud, G., and Grinstein, S. (1993) J. Biol. Chem. 268, 3357-3363 [Abstract/Free Full Text]
  52. Simon, M. I., Strathmann, M. P., and Gautam, N. (1991) Science 252, 802-808 [Medline] [Order article via Infotrieve]
  53. Taylor, S. J., Chae, H. Z., Rhee, S. G., and Exton, J. H. (1991) Nature 350, 516-518 [CrossRef][Medline] [Order article via Infotrieve]
  54. Katz, A., Wu, D., and Simon, M. I. (1992) Nature 360, 686-689 [CrossRef][Medline] [Order article via Infotrieve]
  55. Wu, D., LaRosa, G. J., and Simon, M. I. (1993) Science 261, 101-103 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.